What is ViAqua Therapeutics?
ViAqua Therapeutics is a biotechnology firm dedicated to addressing critical disease management challenges within the aquaculture industry. The company is pioneering an oral delivery platform for nucleic acid-based solutions aimed at enhancing the health of marine species. This innovative approach is crucial for advancing sustainable aquaculture practices, which are increasingly hampered by disease prevention and treatment difficulties. Headquartered in Haifa, Israel, ViAqua Therapeutics is positioned at the forefront of biotech innovation for aquatic health.
How much funding has ViAqua Therapeutics raised?
ViAqua Therapeutics has raised a total of $12.6M across 2 funding rounds:
Other Financing Round
$4.3M
Other Financing Round
$8.3M
Other Financing Round (2021): $4.3M with participation from S2G Ventures, Thai Union, Agriline Products, VisVires New Protein, Technion Israel Institute of Technology, Nutreco, and The Trendlines Group
Other Financing Round (2023): $8.3M led by S2G Ventures and Rabo Frontier Ventures
Key Investors in ViAqua Therapeutics
S2G Ventures
S2G Ventures is a multi-stage venture fund focused on food and agriculture, investing in companies that align with shifting consumer demands for healthy and sustainable food. They seek leadership positions in emerging markets across the food supply chain.
Rabo Frontier Ventures
Rabo Frontier Ventures is an investment fund of Rabobank, concentrating on innovative Fintech and Agtech companies globally. They invest in early growth-stage companies disrupting Rabobank's business areas.
Thai Union
Thai Union is a major producer of seafood-based food products, including tuna, shrimp, and pet food, operating globally from its base in Thailand.
What's next for ViAqua Therapeutics?
The substantial enterprise-level and strategic investment in ViAqua Therapeutics signals a strong market confidence in its biotechnology-driven approach to aquaculture health. This capital infusion is expected to accelerate the development and commercialization of its oral delivery platform, potentially expanding its reach into new markets and applications. The company's focus on sustainable solutions aligns with global trends, positioning it for significant growth and impact in the rapidly evolving aquaculture sector. Future strategic initiatives will likely involve scaling production, further research and development, and forging key industry partnerships.
See full ViAqua Therapeutics company page
